Cansino Biologics

Cansino Biologics's reported carbon emissions

**CanSino Biologics Carbon Emissions and Climate Commitments** For the fiscal year 2024, Cansino Biologics reported a total of approximately 256,445,240 kg CO2e in greenhouse gas emissions. This figure encompasses Scope 1, Scope 2, and Scope 3 emissions. In 2023, the company's total emissions were approximately 223,329,590 kg CO2e. This was a decrease from the approximately 234,840,950 kg CO2e reported in 2022. For 2021, total emissions were approximately 35,159,360 kg CO2e, with Scope 1 and Scope 2 emissions detailed, but no Scope 3 total was provided. Cansino Biologics has set clear climate targets. They aim to reduce total greenhouse gas (GHG) emissions per floor area by 40% by 2025 and by 50% by 2030, using 2021 as the benchmark year. These targets apply to both Scope 1 and Scope 2 emissions. Specifically, they have an absolute reduction target of 50% for Scope 2 emissions by 2030. The company, headquartered in China and operating within the Pharmaceutical Preparation Manufacturing industry, has disclosed emissions data for Scopes 1, 2, and 3 across several reporting years. Specific emissions for Scope 1 in 2024 include approximately 1,3460 kg CO2e from mobile combustion, 668,610 kg CO2e from fugitive emissions, and 1,176,730 kg CO2e from stationary combustion. Scope 2 emissions in 2024 were primarily from purchased steam, amounting to approximately 11,725,300 kg CO2e. Scope 3 emissions for 2024 included approximately 221,993,220 kg CO2e from waste generated in operations and 17,485,910 kg CO2e from fuel and energy-related activities. The provided data indicates that Cansino Biologics is committed to tracking and reducing its environmental impact, with specific intensity-based and absolute reduction targets for GHG emissions.